Search

Navigating GLP-1 and Pregnancy: Insights, Safety, and Postpartum Considerations

4.8 (519) · $ 8.50 · In stock

Navigating GLP-1 and Pregnancy: Insights, Safety, and Postpartum  Considerations
Abstracts from ATTD 2017 10th International Conference on Advanced  Technologies & Treatments for Diabetes Paris, France—February 15–18, 2017

Abstracts from ATTD 2017 10th International Conference on Advanced Technologies & Treatments for Diabetes Paris, France—February 15–18, 2017

GLP-1 vs. Lifestyle Changes: What is More Effective for Weight

GLP-1 vs. Lifestyle Changes: What is More Effective for Weight

JPM, Free Full-Text

JPM, Free Full-Text

Metabolic and feeding adjustments during pregnancy

Metabolic and feeding adjustments during pregnancy

The 4th International Conference onAdvanced Technologies & Treatments for  DiabetesLondon, UK/February 16–19, 2011

The 4th International Conference onAdvanced Technologies & Treatments for DiabetesLondon, UK/February 16–19, 2011

Frontiers  From Maternal Diet to Neurodevelopmental Disorders: A Story of  Neuroinflammation

Frontiers From Maternal Diet to Neurodevelopmental Disorders: A Story of Neuroinflammation

The Fourth Trimester: a Time for Enhancing Transitions in Cardiovascular  Care

The Fourth Trimester: a Time for Enhancing Transitions in Cardiovascular Care

Metformin in Pregnancy, PDF, Gestational Diabetes

Metformin in Pregnancy, PDF, Gestational Diabetes

Pregestational Diabetes Mellitus - Endotext - NCBI Bookshelf

Pregestational Diabetes Mellitus - Endotext - NCBI Bookshelf

Frontiers  The metabolic conditioning of obesity: A review of the  pathogenesis of obesity and the epigenetic pathways that “program” obesity  from conception

Frontiers The metabolic conditioning of obesity: A review of the pathogenesis of obesity and the epigenetic pathways that “program” obesity from conception

PDF) Sex Differences in Response to Treatment with Glucagon-like Peptide 1  Receptor Agonists: Opportunities for a Tailored Approach to Diabetes and  Obesity Care

PDF) Sex Differences in Response to Treatment with Glucagon-like Peptide 1 Receptor Agonists: Opportunities for a Tailored Approach to Diabetes and Obesity Care